Organization and Nature of Business (Details) - USD ($)		6 Months Ended
	Nov. 01, 2019	Dec. 31, 2020
Cash upon completion of Phase I Clinical Trials	$ 1,500,000
Cash upon completion of Phase II Clinical Trials	2,500,000
Cash upon completion of Phase III Clinical Trials	$ 5,000,000
TheraCour
Issuance of shares	75,000
Cash upon completion of Phase I Clinical Trials	$ 1,500,000
Cash upon completion of Phase II Clinical Trials	2,500,000
Cash upon completion of Phase III Clinical Trials	$ 5,000,000
Percentage of Net Sales Allocated for Royalty Payments	15.00%	15.00%
Series A Convertible Preferred Stock [Member]
Issuance of shares	75,000